Navigation Links
Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
Date:3/8/2013

IRVING, Texas, March 8, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, will sponsor an expert symposium, Integrating Next Generation Sequencing Into the Clinical Management of Gynecologic Cancers, at the 2013 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer® in Los Angeles, Calif.

The symposium, which will take place Sunday, March 10, at 1 p.m. PDT, is designed to update the gynecologic oncology community on technological and clinical advances that may impact and shape the management and therapy optimization for gynecologic cancers both today and in the near future. The program will feature presentations by several prominent experts in the application of tumor profiling in gynecologic oncology.

The expert panel will also discuss the clinical importance of utilizing a multi-platform approach, such as that provided by Molecular Intelligence™ Services, when profiling gynecological malignancies. Molecular Intelligence from Caris Life Sciences is the world's foremost evidence‐based tumor profiling service, providing oncologists with relevant, clinically actionable and individualized treatment information to personalize therapy regimens for their cancer patients.

"Recent technological advances, including the introduction of next generation sequencing (NGS), have expanded the ability to more rapidly and broadly profile gynecological malignancies," said symposium course director Robert Coleman , M.D., professor of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas. "This symposium will provide a glimpse into how this emerging tool has enabled significantly improved access to genetic information from cancer patients, many times revealing critical insights about the genomics of the disease."

The application of NGS technologies holds significant promise in the treatment of ovarian cancer, the most lethal gynecologic cancer in the U.S., resulting in approximately 14,000 deaths annually.1 Although primary ovarian carcinomas initially respond to platinum-based therapy, this response is often incomplete, resulting in relapse in almost 80% of women with advanced disease.2‐4 It's therefore critical to thoroughly assess the entire biology of a tumor using NGS technology, along with more traditional profiling technologies like IHC and FISH.

"Given the high recurrence rate and poor long‐term survival of women with advanced ovarian cancer, there is an urgent need for improved methods of biomarker target identification, chemotherapy selection and clinical trials enrollment," explained Dr. Coleman. "Ovarian neoplasms differ widely with respect to their clinical behavior and response to chemotherapy, suggesting that each patient's disease may harbor unique, clinically actionable molecular targets. When paired with traditional gold-standard pathology, NGS information has the promise to lead to superior therapeutic associations, more rapid and efficient identification of candidates for new clinical trials, and ultimately, better patient management."

In addition to Dr. Coleman, the symposium faculty includes the below experts, whose presentations will address the following topics:

  • NGS Targets in Ovarian Carcinoma: Ryan Bender , Ph.D, FACMG, Director, Molecular Genetics, Caris Life Sciences
  • Integrating NGS Data Into Patient Care – Today: Deborah Zajchowski , Ph.D, Clearity Foundation
  • The Future of Tumor Profiling in Gynecologic Cancers: Maurie Markman , M.D., SVP & National Director of Medical Oncology, Cancer Treatment Centers of America

About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of personalized medicine. Caris' Molecular Intelligence™ Service (MI Profile™) correlates molecular data generated from a patient's tumor with biomarker/drug associations derived from the world's leading clinical cancer literature. This service uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company's proprietary Carisome® platform — a blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe, and other international markets. To learn more, please visit www.carislifesciences.com.

References:

  1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society, 2013.
  2. Cannistra SA. Cancer of the Ovary. N Engl J Med 1993;329:1550-9.
  3. Thigpen JT, Vance RB, Khansur T. Second-line therapy for recurrent ovarian carcinoma of the ovary. Cancer 1993;71:1559-64.
  4. Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia, PA: Lippincott; 1992:731-81.


'/>"/>
SOURCE Caris Life Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
2. Caris Life Sciences mejora la evaluación por perfil molecular con los biomarcadores ROS1 y MGMT-metilación
3. Caris Sponsors CancerCare Connect Education Workshop on Molecular Profiling in the Treatment of Breast Cancer
4. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
5. Caris Life Sciences nimmt Next-Generation Sequencing zur Verbesserung des evidenzbasierten Tumorprofilierungsservices für Krebspatienten auf
6. Garage Start-ups Now Possible in Life Sciences Industry
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. DiaTech Life Sciences Announces Medical Advisory Board
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... in a published evaluation of multiple immunoassay-based threat detection technologies by researchers ... Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have the ...
(Date:2/23/2017)... Aviva Systems Biology Corporation (ASB) which ... GenWay Biotech Incorporated, a protein solutions and applications ... for both the research and diagnostic markets. ... capabilities for both entities. GenWay,s 18 years of experience ... complement ASB,s objective to become a leading provider ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Park Systems ... free AFM Luncheon for all SPIE attendees and Park customers on ... one block from the San Jose Convention Center. The luncheon will feature a ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, is pleased to ... on February 22 and 23, 2017. This premier, online-only conference focused on the ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):